ReviewACS omega2023
Thermocatalytic Decomposition of Methane: A Review on Carbon-Based Catalysts.
Review in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 96 citations in OpenAlex.
- Hydrogen (HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Investigation of Coked Catalyst Regeneration via Non-Thermal Plasma Treatment and Its Reuse for Hydrogen Production from Methane Pyrolysis.Molecules (Basel, Switzerland) · 2026Article
- The Kinetic Consequences of Water on Catalytic Methane Pyrolysis.ACS catalysis · 2026Article
- Thermocatalytic Behavior of TiOACS omega · 2026Article
- Effect of the Reactor Material on the Reforming of Primary Syngas.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global initiatives on sustainable and green energy resources as well as large methane reserves have encouraged more research to convert methane to hydrogen. Catalytic decomposition of methane (CDM) is one optimistic route to generate clean hydrogen and value-added carbon without the emission of harmful greenhouse gases, typically known as blue hydrogen. This Review begins with an attempt to understand fundamentals of a CDM process in terms of thermodynamics and the prerequisite characteristics of the catalyst materials. In-depth understanding of rate-determining steps of the heterogeneous catalytic reaction taking place over the catalyst surfaces is crucial for the development of novel catalysts and process conditions for a successful CDM process. The design of state-of-the-art catalysts through both computational and experimental optimizations is the need of hour, as it largely governs the economy of the process. Recent mono- and bimetallic supported and unsupported materials used in CDM process have been highlighted and classified based on their performances under specific reaction conditions, with an understanding of their advantages and limitations. Metal oxides and zeolites have shown interesting performance as support materials for Fe- and Ni-based catalysts, especially in the presence of promoters, by developing strong metal-support interactions or by enhancing the carbon diffusion rates. Carbonaceous catalysts exhibit lower conversions without metal active species and largely result in the formation of amorphous carbon. However, the stability of carbon catalysts is better than that of metal oxides at higher temperatures, and the overall performance depends on the operating conditions, catalyst properties, and reactor configurations. Although efforts to summarize the state-of-art have been reported in literature, they lack systematic analysis on the development of stable and commercially appealing CDM technology. In this work, carbon catalysts are seen as promising futuristic pathways for sustained H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.